SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

BTIG maintains $46 price target on Maze Therapeutics

Ratings actions from Benzinga: BTIG maintained a $46.00/share price target on Maze Therapeutics.

MAZE

Related stories